AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12736155
Drug: d-arginine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-arginine (1 g/min for 30 min)
Trial: 11050518
Drug: Droperidol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg i.v. (group 1)
Trial: 11050518
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg i.v. (group 2)
Trial: 11050518
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (droperidol + ondansetron)
Trial: 26365210
Drug: Lifitegrast ophthalmic
RxNorm normalized name: lifitegrast ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifitegrast ophthalmic solution 5.0%, twice daily for 84 days
Trial: 30112930
Drug: Lifitegrast ophthalmic
RxNorm normalized name: lifitegrast ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifitegrast ophthalmic solution 5.0%
Trial: 23334069
Drug: Ponezumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponezumab (all doses)
Trial: 21062338
Drug: Switching platform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching platform implants
Trial: 15823764
Drug: Oxycodone 5
RxNorm normalized name: oxycodone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 5 mg
Trial: 15823765
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet (Oxycodone 5 mg + Ibuprofen 400 mg)
Trial: 11565840
Drug: TGF-β3 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF-β3 (25 μg/mL) applied as mouthwash four times daily
Trial: 2972167
Drug: Danazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (200 mg 3 times daily)
Trial: 31661809
Drug: Detoxification intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Detoxification intervention (exercise, sauna-induced sweating, crystalline nicotinic acid, and other supplements)
Trial: 28434014
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg on the first day, followed by 100 mg once daily for 12 weeks)
Trial: 15789980
Drug: Oral-B Indicator
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B Indicator toothbrush
Trial: 11502643
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg vesnarinone
Trial: 2589534
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg im atropine (ATR)
Trial: 11410074
Drug: Petadolex (Petasites
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petadolex (Petasites hybridus extract), 25 mg per capsule, 2 capsules twice daily for 12 weeks
Trial: 1927240
Drug: 2% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% mepivacaine with 0.1 mg fentanyl
Trial: 19054193
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi Chuan training for 1 hour twice a week for 13 weeks
Trial: 16907703
Drug: alpha2B C/A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha2B C/A polymorphism in both whites and African-Americans taking beta-blockers
Trial: 7654891
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg daily
Trial: 9654800
Drug: School-based alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based alcohol and drug abuse prevention program
Trial: 3046299
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin E supplementation at doses up to 3200 mg/d (3200 IU/d)
Trial: 3320325
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin E supplementation
Trial: 29651816
Drug: Weekly theoretical
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly theoretical and hands-on guidance from dental hygienists on oral hygiene procedures and discussions on oral care routines
Trial: 24178765
Drug: Alcohol (vodka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (vodka 37.5% at a dose of 46.5 g ethanol)
Trial: 24178765
Drug: Alcohol in
RxNorm normalized name: WATER/BENZYL ALCOHOL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol in combination with caffeine at a dose of 80 mg
Trial: 24178765
Drug: Alcohol in
RxNorm normalized name: WATER/BENZYL ALCOHOL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol in combination with energy drink at a dose of 250 ml
Trial: 21175704
Drug: Generic omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic omeprazole 20 mg once daily
Trial: 18511540
Drug: Topical travoprost
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical travoprost 0.004% once daily for 6 months
Trial: 16970646
Drug: Mid-morning nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-morning nutritional supplement for 3 weeks
Trial: 14556728
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) 0.05-0.1 mg/kg per day
Trial: 24374115
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg over 45 min, second dose)
Trial: 24374115
Drug: ECT (electroconvulsive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT (electroconvulsive therapy, administered on 3 test days every 48 hours)
Trial: 21365332
Drug: Intravesical instillations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillations with 40 ml chondroitin sulfate 0.2% solution
Trial: 18959492
Drug: Viral suppression
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viral suppression (continued use of antiretroviral therapy)
Trial: 18959492
Drug: Drug conservation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug conservation (interrupt antiretroviral therapy until CD4(+) cell count <250 cells/microL)
Trial: 14567368
Drug: Ciclopirox gel
RxNorm normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox gel vehicle applied twice daily for 28 days
Trial: 8765259
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (ethinyl estradiol 0.02 mg, desogestrel 0.15 mg) combined with oral danazol 50 mg a day for 21 days of each 28‐day cycle
Trial: 1389821
Drug: Separate infusions
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate infusions of propofol and alfentanil
Trial: 6698659
Drug: Mepindolol sulfate
RxNorm normalized name: mepindolol sulfate
DrugBank: Mepindolol (DB13530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepindolol sulfate 2 X 2.5 mg daily
Trial: 28929168
Drug: Ixekizumab (80-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (80-mg every 4 weeks)
Trial: 24617961
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) administered via telemedicine, 10 weekly therapy sessions
Trial: 24617961
Drug: Traditional face-to-face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional face-to-face therapy
Trial: 24308672
Drug: TXA-250 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA-250 group (TXA 250 mg)
Trial: 24308672
Drug: TXA-500 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA-500 group (TXA 500 mg)
Trial: 19000558
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation containing 1,000 mg levetiracetam
Trial: 10333196
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg o.d. plus azithromycin 500 mg o.d. and tinidazole 500 mg b.i.d. (PAT)
Trial: 7723896
Drug: Diiodohydroxyquinolein (DQ)
RxNorm normalized name: diiodohydroxyquinoline
DrugBank: Diiodohydroxyquinoline (DB09115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diiodohydroxyquinolein (DQ) (80 mg/day p.o.)
Trial: 7723896
Drug: Zn sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc (DB01593)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zn sulfate plus DQ (100 mg/day Zn sulfate and 80 mg/day DQ p.o.)
Trial: 23922179
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g/kg for men, 0.75 g/kg for women)
Trial: 21288119
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management (optional treatment module for ADHD)
Trial: 7398002
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (ASA)
Trial: 9054843
Drug: Combined ticlopidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ticlopidine and aspirin (TIC-ASA)
Trial: 9448657
Drug: risperidone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone (2 mg/day)
Trial: 7683702
Drug: risperidone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone (6 mg/day)
Trial: 9448657
Drug: risperidone (6-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone (6-16 mg/day)
Trial: 9448657
Drug: haloperidol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol (20 mg/day)
Trial: 7683702
Drug: risperidone (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone (2, 6, and 16 mg/day)
Trial: 3727918
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid 300 mg/day
Trial: 12418118
Drug: Propranolol 120
RxNorm normalized name: propranolol 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 120 mg/day
Trial: 9024711
Drug: Anastrozole 10
RxNorm normalized name: anastrozole 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 10 mg
Trial: 27259315
Drug: Levobupivacaine (0.75%)
RxNorm normalized name: levobupivacaine 0.75 MG/ML
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (0.75%) with 5 μg mL(‐1) of adrenaline, injected at T 8‐9 interspace, dosage: 1.8 mg kg(‐1), duration: 1.5 min
Trial: 23439942
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 0.15% benzydamine hydrochloride
Trial: 23439942
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 0.9% normal saline
Trial: 17387026
Drug: Aceclofenac 100
RxNorm normalized name: aceclofenac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac 100 mg twice daily
Trial: 11961179
Drug: meloxicam 7.5
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam 7.5 mg bid
Trial: 20828790
Drug: naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg bid
Trial: 9584497
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation of 1000 mg/day
Trial: 2137322
Drug: Oral ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ketoconazole therapy
Trial: 24461572
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral stimulation)
Trial: 26829012
Drug: Cabazitaxel with
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel with G-CSF
Trial: 24251969
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (1000 mg single administration)
Trial: 24251969
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (200 mg daily for 3 months)
Trial: 16191850
Drug: Short contact
RxNorm normalized name: BenzePrO Short Contact 9.8 % Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short contact dithranol treatment
Trial: 12577228
Drug: Gemcitabine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine combined with bolus or infusional 5‐fluorouracil, capecitabine, metalloproteinase inhibitors, or FTI tipifarnib
Trial: 9578187
Drug: MKS492 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MKS492 40 mg
Trial: 9578187
Drug: MKS492 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MKS492 20 mg
Trial: 2547540
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of Hyalgan (HA, Na-hyaluronate, 20 mg/2 ml)
Trial: 17244295
Drug: Cash and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cash and Counseling (treatment group)
Trial: 12544376
Drug: Alprazolam 0.25
RxNorm normalized name: alprazolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.25 mg
Trial: 21288144
Drug: Alprazolam 0.5
RxNorm normalized name: alprazolam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.5 mg
Trial: 12544376
Drug: Alprazolam 1
RxNorm normalized name: alprazolam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 1 mg
Trial: 22762200
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (21 mg) after overnight smoking abstinence
Trial: 14967093
Drug: Unique diagnosis-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unique diagnosis-treatment pairs analysis
Trial: 11285108
Drug: Interactive computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive computer use with weekly nurse training
Trial: 15553106
Drug: cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetirizine 10 mg o.d.
Trial: 25296147
Drug: Workplace Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Workplace Exercise (twice a week for 15 minutes over 10 weeks)
Trial: 21138634
Drug: Nucleoside analogue
RxNorm normalized name: Nucleoside analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside analogue therapy (middle stage)
Trial: 19910033
Drug: Omalizumab (75-375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (75-375 mg sc, q2 or q4 wk)
Trial: 12694432
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (n=24)
Trial: 12694432
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (control, n=15)
Trial: 3535127
Drug: Cefixime 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 400 mg once daily
Trial: 11605809
Drug: Cefixime 200
RxNorm normalized name: cefixime 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 200 mg twice daily
Trial: 28958502
Drug: Dacomitinib 45
RxNorm normalized name: dacomitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib 45 mg/day
Trial: 23862170
Drug: 14-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day triple therapy
Trial: 22654429
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy
Trial: 21435093
Drug: 14-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day sequential therapy
Trial: 21840917
Drug: Robot‐assisted therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot‐assisted therapy
Trial: 19672708
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg + Rabeprazole 10 mg
Trial: 19672708
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg + Rabeprazole 40 mg
Trial: 11821508
Drug: Topical clobetasol
RxNorm normalized name: clobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol propionate cream (40 g per day)
Trial: 11821508
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (0.5 mg/kg/day for moderate disease and 1 mg/kg/day for extensive disease)
Trial: 9951426
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg twice a day for 5 days)
Trial: 9951426
Drug: Pimozide (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimozide (6 mg oral dose)
Trial: 4042390
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg twice daily
Trial: 7752176
Drug: Furosemide 60
RxNorm normalized name: furosemide 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 60 mg twice daily
Trial: 6993446
Drug: Alprazolam (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1.5 mg/day)
Trial: 31532960
Drug: Maribavir (400,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maribavir (400, 800, or 1200 mg twice daily)
Trial: 31532960
Drug: Valganciclovir (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir (standard dose)
Trial: 16053779
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment
Trial: 19767089
Drug: Methotrexate 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice a day on days 2-3 (n=39)
Trial: 19767089
Drug: Methotrexate 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 3.5 g/m(2) on day 1 (n=40)
Trial: 14722639
Drug: Heparin-coated catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated catheter
Trial: 11478138
Drug: LH-RH agonist
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-RH agonist combined with tamoxifen
Trial: 11478138
Drug: LH-RH agonist
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-RH agonist alone
Trial: 31420383
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide (NO) at 20 ppm administered into the CPB oxygenator for the duration of CPB
Trial: 23340885
Drug: myo-inositol plus
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: myo-inositol plus 200 µg folic acid twice a day
Trial: 23340885
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 µg folic acid twice a day)
Trial: 21830396
Drug: Supplement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement of 200kcal before endoscopic therapy (n=18)
Trial: 21830396
Drug: No energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No energy supplied (fasting group) before endoscopic therapy (n=18)
Trial: 19880429
Drug: MEN11420 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEN11420 2 mg
Trial: 19880429
Drug: MEN11420 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEN11420 8 mg
Trial: 16309383
Drug: Intra-arterial TNF-alpha
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial TNF-alpha infusion
Trial: 15639689
Drug: Tramadol LP
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol LP 200 mg once daily
Trial: 11157012
Drug: Combined-modality therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality therapy (neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil or cyclophosphamide, doxorubicin, vincristine, and prednisone, followed by local therapy and radiotherapy)
Trial: 2898536
Drug: Combined-modality therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality therapy
Trial: 28454553
Drug: Ambulatory oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory oxygen used during daily activities for a 2-week period at an optimal flow rate determined by titration at screening visit.
Trial: 21924624
Drug: Muscle vibration
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle vibration intervention (12×4 min daily at 100Hz, 0.3mm amplitude) during immobilization
Trial: 16696910
Drug: Xuezhikang Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang Capsules (ZXKC)
Trial: 11697808
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day of alendronate, 0.50 microg/day of calcitriol, and 500 mg/day of calcium carbonate